Press release
Sandhoff Disease Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Sandhoff Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Sandhoff Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Sandhoff Disease Pipeline Report
* DelveInsight's Sandhoff Disease Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Sandhoff Disease treatment.
* The leading Sandhoff Disease Companies such as IntraBio, Sanofi, Polaryx Therapeutics, Azafaros and others.
* Promising Sandhoff Disease Pipeline Therapies such as IB1001, Zavesca (Miglustat), TSHA-101, Miglustat and others.
Stay ahead with the most recent pipeline outlook for Sandhoff Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Sandhoff Disease Treatment Drugs [https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Sandhoff Disease Emerging Drugs Profile
* IB1001: IntraBio
IB1001, N-acetyl-L-leucine, is an orally administered modified amino acid. In vivo studies have identified N-acetyl-L-leucine to be the active isomer of N-acetyl-DL-leucine and can restore neuronal function and protect against/delay disease progression in multiple neurological circuits of the brain. The mechanism of N-acetyl-L-leucine is known to be multi-modal, including altered glucose and antioxidant metabolism, reduced lysosomal storage, and the reduction of neuroinflammation in the cerebellum, leading to the attenuation of cell death. The company is conducting a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease).
* Venglustat: Sanofi
Venglustat is a novel, oral investigational therapy that has the potential to slow the progression of certain diseases by inhibiting abnormal glycosphingolipid (GSL) accumulation. GSLs are cellular building blocks whose abnormal accumulation is implicated in several rare diseases, responsible for both cell dysfunction and disease progression.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Sandhoff Disease.
The Sandhoff Disease Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Sandhoff Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sandhoff Disease Treatment.
* Sandhoff Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Sandhoff Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sandhoff Disease market
Explore groundbreaking therapies and clinical trials in the Sandhoff Disease Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Sandhoff Disease Drugs [https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Sandhoff Disease Companies
IntraBio, Sanofi, Polaryx Therapeutics, Azafaros and others.
Sandhoff disease Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Sandhoff Disease Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Sandhoff Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Sandhoff Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Sandhoff Disease Pipeline Report
* Coverage- Global
* Sandhoff Disease Companies- IntraBio, Sanofi, Polaryx Therapeutics, Azafaros and others.
* Sandhoff Disease Pipeline Therapies- IB1001, Zavesca (Miglustat), TSHA-101, Miglustat and others.
* Sandhoff Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Sandhoff Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Sandhoff Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Sandhoff Disease Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Sandhoff disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Sandhoff disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Venglustat: Sanofi
* Drug profiles in the detailed report.....
* Mid-Stage Products (Phase II)
* IB1001: IntraBio
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Sandhoff disease Key Companies
* Sandhoff disease Key Products
* Sandhoff disease- Unmet Needs
* Sandhoff disease- Market Drivers and Barriers
* Sandhoff disease- Future Perspectives and Conclusion
* Sandhoff disease Analyst Views
* Sandhoff disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sandhoff-disease-pipeline-appears-robust-with-5-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sandhoff-disease-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sandhoff Disease Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4026997 • Views: …
More Releases from ABNewswire
Quest Auto Sales Transforms Used Cars for Sale Market with a Customer-First Fina …
Quest Auto Sales at 4501 L St, Omaha, offers flexible financing and transparent pricing on pre-owned vehicles, driving growth through customer referrals and personalized service in the local market.
The pre-owned vehicle market in Omaha is shifting as Quest Auto Sales [https://www.questautosales.com/] introduces a financing approach that prioritizes customer needs over rigid sales quotas. Located at 4501 L St in Omaha, NE 68117, the dealership has built its reputation on flexible…
Crown Reconstruction Services Inc. Introduces Transparent Pricing Model for Roof …
Crown Reconstruction Services Inc. in Laguna Beach introduces itemized pricing for roofing projects, giving property owners detailed cost breakdowns before work begins.
A Laguna Beach-based contractor is addressing one of the construction industry's most persistent challenges: pricing transparency. Crown Reconstruction Services Inc. [https://crownreconstructionservices.com/], operating from its office at 2055 Laguna Canyon Rd, has implemented a new pricing structure that provides homeowners with detailed, itemized estimates before any work begins.
The roofing industry…
Blue Ocean Life Brings Ocean-Inspired Calm, Resilience, and Freedom to Everyday …
Blue Ocean Life Company LLC spreads a message of healing, balance, and coastal calm through its mission-driven apparel and lifestyle brand. With designs like "Saltwater Heals Everything" and "Find Your Calm," the Cape Cod-based company blends style with purpose, reminding people of the restorative power of the ocean while addressing rising mental health challenges through lifestyle design.
CAPE COD, Mass. - Blue Ocean Life Company LLC is spreading a message of…
Third Hemisphere Strengthens Position as Leading Investment Communications Speci …
Jeremy Liddle [https://thirdhemisphere.agency/about-us] Third Hemisphere has established itself as a specialist in alternative investment communications, expanding capabilities across private credit, growth equity, and venture capital. The agency's regional positioning reflects the increasing sophistication of the Asia-Pacific investment landscape, where institutional allocators are diversifying beyond traditional public markets into private and alternative asset strategies.
The alternative investment environment in the region demands communications expertise that integrates financial understanding, Third Hemisphere, a full…
More Releases for Sandhoff
Sandhoff Disease Market to Reach USD 1.2 Billion by 2034
Sandhoff disease is a rare, inherited lysosomal storage disorder caused by mutations in the HEXB gene, leading to a deficiency in the beta-hexosaminidase A and B enzymes. This deficiency results in the accumulation of GM2 gangliosides within nerve cells, causing progressive neurodegeneration. Sandhoff disease presents in various forms-infantile, juvenile, and adult-onset-with the infantile type being the most severe and often fatal by early childhood.
Download Full PDF Sample Copy of Market…
Sandhoff Disease Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Sandhoff Disease Pipeline Insight 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Sandhoff Disease pipeline landscape. It covers the Sandhoff Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sandhoff Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Sandhoff Disease pipeline products in this space.
Discover the latest drugs…
Sandhoff Disease Pipeline: 5+ Biotech Firms Driving Rare Disease Innovation Thro …
Sandhoff Disease, a rare and fatal lysosomal storage disorder, is seeing progress through the efforts of over 5 companies, including IntraBio, Sanofi, Polaryx Therapeutics, and Azafaros. The Sandhoff pipeline primarily focuses on gene therapy, substrate reduction, and enzyme replacement therapies aimed at correcting the underlying enzyme deficiency. Despite its ultra-rare prevalence, advancements in AAV-based vectors and CNS-targeted delivery systems are driving a new era of hope for patients and caregivers…
Sandhoff Disease Market Size, Share, Trends, Growth 2024-2032
The Sandhoff disease market size was valued at USD 10.18 billion in 2023, driven growing interest in gene therapy as a potential curative approach across the major markets. The market size is anticipated to grow at a CAGR of 5.87% during the forecast period of 2024-2032 and attain a value of USD 17 billion by 2032.
Sandhoff Disease:
Sandhoff disease is a rare, inherited genetic disorder characterized by the harmful accumulation of…
Sandhoff Disease Treatment Market Analysis: Understanding Trends, Players, and P …
"Sandhoff Disease Treatment Market Is Growing At A Steady Cagr During Forecast Period".
With thorough company profiles, recent developments, and other information, the Sandhoff Disease Treatment Market Report provides an in-depth analysis of major trends, motivating reasons, obstacles, segmentation, regulatory policies, and important players. The Sandhoff Disease Treatment Market Report offers a thorough synopsis of the product portfolio, including product development, planning, and positioning of products with emerging technologies, impending opportunities,…
Sandhoff Disease Market: Analysis of Epidemiology, Industry Trends, Size, Share, …
IMARC Group has recently released a report titled "Sandhoff Disease Market : Analysis of Epidemiology, Industry Trends, Size, Share, and Future Forecast (2023-2033)" that presents a comprehensive assessment of the sandhoff disease market size . The report provides an extensive overview of the latest market trends, growth prospects, investment opportunities, and industry outlook, as well as an in-depth analysis of the disease landscape, market size, and growth trends. Furthermore, the…
